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Abstract
Antimicrobial peptides (AMPs), also known as host defense peptides, are small and mostly polycationic
molecules that form part of the innate immune response. There are currently more than 3000 experimentally
reported AMPs. Particularly in frogs, the temporin family has been discovered as potential AMPs. The aim of
this work is to review the latest publications about this class of peptides, discuss their properties, and present an
update of the last studies and new discoveries in the field. More than 130 temporins have been identified in
this family. The most studied temporins are temporin A (TA), temporin B (TB), and temporin L (TL). These
peptides showed antimicrobial activity against gram-negative, gram-positive bacteria and fungi. Since the
discovery of temporins in 1996, several groups of researchers isolated different peptides from various species of
frogs that were included as members of this family. Although antimicrobial activity of many temporins has not
been analyzed yet, most of them showed antimicrobial and antifungal activities. A combination of nanotech-
nology and AMPs for temporins in different antimicrobial treatments could be a promising alternative for
resistant pathogens. These studies demonstrate that, even with the advancement in scientific research on the
composition and antimicrobial activity of temporins, further studies are necessary to wholly understand their
components and mechanisms of action.
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Antimicrobial peptides (AMPs), also known as host de-fense peptides (HDPs), are small and mostly polycationic
molecules that form part of the innate immune response. Most
of the AMPs share common features, such as small size, with
cationic and hydrophobic sequences within a linear or cyclic
structure. The AMPs can inhibit or eliminate bacteria at mi-
cromolar concentrations, often by non-specific mechanisms.
Moreover, AMPs can kill antibiotic-resistant bacteria [1].
Currently, there are more than 3000 reported AMPs, in-
cluding both natural peptides produced by living organisms
from protozoa to animals and plants and artificial synthetic
peptides. The vast number of compounds with known biologic
activities are listed in specialized AMP databases such as the
Antimicrobial Peptide Database 3 (APD3, [2]), the Collection
of Anti-Microbial Peptides (CAMPR3, [3]) and the Database
Linking Antimicrobial Peptides (LAMP, [4]). This list con-
tains 44 AMP families, including well- known AMPs such as
defensins, brevinines, esculentins, japonicins, nigrocins, pa-
lustrins, ranacyclins, ranatuerins, cecropins, temporins, ma-
gainins, and dermaseptins, some of them studied recently [5].
Frogs (family Ranidae) synthesize a remarkably diverse
range of antimicrobial peptides that are released from the
granular glands to skin secretions in a very high concentration
and a holocrine manner as a consequence of stress or tissue
injury. These peptides serve to protect the frog against inva-
sion by a variety of pathogenic micro-organisms and represent
a component of the innate immunity of these organisms [6,7].
Within this arsenal of defensive peptides, some members of
the temporin family were described [8]. These hydrophobic,
C-terminally a-amidated peptides were first identified in the
skin of the Asian frog Rana erythraea and the European frog
R. esculenta (reclassified as a hybrid between Pelophylax
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ridibundus and P. lessonae) on the basis of their hemolytic
activity [9]. In 1996, Simmaco et al. [10] identified these
peptides in the skin of the European red frog R. temporaria.
Later, they were also discovered in frogs of Northern America
and Eurasian origin as well as in the venom of wasps [11,12].
Previous reports reviewed only 75 temporins. In addition,
in the last five years, new members of this family were de-
scribed in different frog species and studied for antimicrobial
activity. Moreover, new approaches for pharmacologic dis-
coveries, drug delivery, and nanotechnology have been ap-
plied using temporins because of their interesting properties
and the well-known antimicrobial activity. In particular, two
of the most studied temporins (temporin A and B) were used
recently as potential candidates in medical and molecular
new researches.
The aim of this work is to review the latest publications
concerning this family of peptides, discuss their properties
and potential applications, and provide an update of the last
studies and new discoveries in the field.
Temporins
Initially, temporins were described as ‘‘Vespa-like’’ because
of their structural similarity to the short (13-14 amino acids)
peptides with chemotactic and histamine-releasing proper-
ties isolated from the venom of wasps of the genus Vespa [12].
Many peptides from the wasp venom have been used as anti-
microbial drugs for many purposes—for example, intravascu-
lar stents infections [13], and other bacterial [14,15] or fungal
[16]. Temporins present some similarities to these Vespa
peptides—for example, low molecular masses, hydropho-
bic properties, and antimicrobial activity. The derived
amino acid sequence for temporins is FLP(I/L)IASLL(S/G)
KLL-NH2, and the general amino acid type sequence is
X1X2X3X4X5X6Y7X8X9Y10Y11
+X12X13-NH2 (X = hydro-
phobic, Y = hydrophilic and Y+ = charged amino acid).
Hydrophobic residues represent 70% of the peptide se-
quence, leucine being the most abundant amino acid. In ad-
dition, X2, X3, X9, and X13 are highly conserved amino acids
[17]. Most of the temporins adopt an a-helical conformation
in hydrophobic environments [18].
More than 130 members of the temporin family have been
identified in the skins of Eurasian, Asian, and North Ameri-
can ranids (Table 1, [19–66]). The temporins are among the
most highly variable of all antimicrobial peptides. Most
contain a single basic residue (generally Lys) giving a charge
of +1, but several temporins lack this structural feature.
Temporin L, 1-CEa, 1-CEc, 1-CSd, CPa, 1Dra, 1DRb, HN1,
1Lb, 1Lc, LTb, LT2, 1Ola, PRc, PTa, Ra, RN3, and 1TGb
contain two basic residues. In addition, 24 temporins have no
charge and three (CDYa, CDYc, and 1Ja) have acidic amino
acids, with negative charge (Fig. 1). They are C-terminally
a-amidated, and their amino acid sequences are composed
mainly by hydrophobic residues.
Temporins present interesting properties that make them
good candidates for biologic investigation. Some of these
properties are: (1) They are small amphipathic a-helical
AMPs (typically 13 amino acids); (2) they have low positive
net charge at a neutral pH (between 0 and +3); (3) their short
sequence provides low cost-efficient chemical synthesis; (4)
some of the temporins act efficiently against a wide range of
pathogens (bacteria, viruses, filamentous fungi, yeasts, and
protozoa) and are not toxic to mammalian cells; (5) their
mechanism of action is mainly based on cytoplasmic mem-
brane perturbation, but in a different way from that proposed
for the majority of cationic a-helical AMPs; (6) some tem-
porins display antimicrobial and chemotactic activities, im-
munomodulatory effects, and preserve biologic function in
serum; (7) they display synergistic action when combined
with conventional antibiotic agents; (8) they show in vivo
efficacy as topical prophylactic agents against infections and
in vivo anti-endotoxic effects [67,68].
Although most temporins are inhibitors of gram-positive
bacteria, some peptides from this family seem to be atypical
in displaying activity against reference strains of several
clinically relevant gram-negative species and against the
opportunistic yeast pathogen Candida albicans (Fig 2).
The mode of action of the temporin is still uncertain, but
some researchers found that the spatial conformation is es-
sential to penetrate the cell membrane. In general, temporins
adopt an a-helix conformation, although this can change in
different mediums [67,69–71].
Temporins A, B, and L
Temporins A, B, and L are the most studied as antimi-
crobial peptides.
Temporin A
Structure–activity studies with temporin A (TA,
FLPLIGRVLSGIL-NH2) indicated that a hydrophobic N-
terminal residue and bulky hydrophobic residues at positions
5 and 12 are important determinants of antibacterial activity
[68]. The TA is preferentially active against gram-positive
bacteria and has a moderate hemolytic activity [72]. The TA,
together with temporin L, is one of the most studied peptides,
and it was found to show interesting antimicrobial activity.
For example, together with temporin 1P from R. pipiens and
a wasp temporin, TA successfully inhibited the growth of the
fungus Batrachochytrium dendrobatidis, a pathogen associated
with global amphibian declines. In this case, the results ob-
tained with the peptides indicated that the ability to penetrate
membranes and form an a-helical structure was important for
their effectiveness against the pathogen [73]. Also, this peptide
showed antimicrobial activity against Staphylococcus aureus,
Enterococcus faecium, and E. faecalis [74,75].
Wade et al. [76] synthetized a hybrid peptide
(CA(1-7)TA(2-9)NH2 (CATA)), containing portions of the
amino-acid sequences of TA and cecropin A (CA) and eval-
uated its hemolytic, anticoagulant, and antifungal properties.
Cecropin A is a gene encoded antibiotic peptide that was
originally isolated from the silkmoth Hyalophora cecropia
larval hemolymph. In previous works, portions of amino acids
of CA were combined with melittin, a peptide whose sequence
of the amino terminal portion is similar to TA. They found that
both TA and CATA are not hemolytic at concentrations at
which TA yields antimicrobial effects (less than 12mM). The
CATA has a weaker but still significant activity against the
chytrid fungus Batrachochytrium dendrobatidis. While TA
does not affect coagulation times at the concentrations studied,
CATA inhibits coagulation at all concentrations tested [76].
In another study, TA structure was modified to make three
different analogues: A monomeric carboxy peptide (TAc), a
dimeric temporin (TAd), and a synthesized analogue using a




















































Table 1. Updated List of Temporins Described since First Discovery in 1996
Temporin Amino acid sequence
No.
amino







A FLPLIGRVLSGIL-NH2 13 Rana temporaria +1 1 0 [10]
B LLPIVGNLLKSLL-NH2 13 Rana temporaria +1 1 0 [10]
C LLPILGNLLNGLL-NH2 13 Rana temporaria 0 0 0 [10]
D LLPIVGNLLNSLL-NH2 13 Rana temporaria 0 0 0 [10]
E VLPIIGNLLNSLL-NH2 13 Rana temporaria 0 0 0 [10]
F FLPLIGKVLSGIL-NH2 13 Rana temporaria +1 1 0 [10]
G FFPVIGRILNGIL-NH2 13 Rana temporaria +1 1 0 [10]
H LSPNLLKSLL-NH2 10 Rana temporaria +1 1 0 [10]
K LLPNLLKSLL-NH2 10 Rana temporaria +1 1 0 [10]
L FVQWFSKFLGRIL-NH2 13 Rana temporaria +2 2 0 [10]
1ARa FLPIVGRLISGLL-NH2 13 Rana areolata +1 1 0 [19]
1AUa PLPIIGQLLSGLL-NH2 13 Rana aurora aurora 0 0 0 [20]
ALa FLPIVGKLLSGLSGLL-NH2 16 Amolops loloensis +1 1 0 [21]
Alb FLPIVGKLLSGLL-NH2 13 Amolops loloensis +1 1 0 [22]
ALc LLPIVGKGLSGKL-NH2 13 Amolops loloensis +2 2 0 [22]
ALd FLPIAGKLLSGLSGLL-NH2 16 Amolops loloensis +1 1 0 [22]
ALe FFPIVGKLLFGLSGLL-NH2 16 Amolops loloensis +1 1 0 [22]
ALf FFPIVGKLLSGLSGLL-NH2 16 Amolops loloensis +1 1 0 [22]
ALg FFPIVGKLLFGLFGLL 16 Amolops loloensis +1 1 0 [22]
ALh FLPIVGKLLSGLSGLS-NH2 16 Amolops loloensis +1 1 0 [22]
ALi FFPIVGKLLSGLL-NH2 13 Amolops loloensis +1 1 0 [22]
ALj FFPIVGKLLFGLL-NH2 13 Amolops loloensis +1 1 0 [22]
ALk FFPIVGKLLS-NH2 10 Amolops loloensis +1 1 0 [22]
1BYa FLPIIAKVLSGLL-NH2 13 Rana boylii +1 1 0 [23]
1Ca FLPFLAKILTGVL-NH2 13 Rana clamitans +1 1 0 [24]
1Cb FLPLFASLIGKLL-NH2 13 Rana clamitans +1 1 0 [24]
1Cc FLPFLASLLTKVL-NH2 13 Rana clamitans +1 1 0 [24]
1Cd FLPFLASLLSKVL-NH2 13 Rana clamitans +1 1 0 [24]
1Ce FLPFLATLLSKVL-NH2 13 Rana clamitans +1 1 0 [24]
1CEa FVDLKKIANIINSIF-NH2 15 Rana chensinensis +1 1 0 [25]
1CEb ILPILSLIGGLLGK-NH2 14 Rana chensinensis +1 1 0 [25]
1CEc IIPLPLGYFAKKT-NH2 13 Rana chensinensis +2 2 0 [25]
CDYa VLPLVGNLLNDLL-NH2 13 Rana dybowskii -1 0 1 [26]
CDYb ILPILAPLIGGLL-NH2 13 Rana dybowskii 0 0 0 [26]
CDYc VLPLVGNLLNDLL-NH2 13 Rana dybowskii -1 0 1 [26]
CDYd FIGPLISALASLFKG-NH2 15 Rana dybowskii +1 1 0 [27a]
CDYe FIGPIISALASLFGG-NH2 15 Rana dybowskii 0 0 0 [27b]
CG1 FLPFVGNLLKGLL-NH2 13 Amolops chunganensis +1 1 0 [28]
CG2 FFPIVGKLLSGLF-NH2 13 Amolops chunganensis +1 1 0 [28]
CG3 FLPIVGKLLSGLF-NH2 13 Amolops chunganensis +1 1 0 [28]
CG4 FLPILGNLLNGLL-NH2 13 Amolops chunganensis 0 0 0 [28]
CG5 FLPFVGNLLNGLL-NH2 13 Amolops chunganensis 0 0 0 [28]
1CSa FLPIVGKLLSGLL-NH2 13 Rana cascadae +1 1 0 [29]
1CSb FLPIIGKLLSGLL-NH2 13 Rana cascadae +1 1 0 [29]
1CSc FLPLVTGLLSGLL-NH2 13 Rana cascadae 0 0 0 [29]
1CSd NFLGTLVNLAKKIL-NH2 14 Rana cascadae +2 2 0 [29]
CPa IPPFIKKVLTTVF-NH2 13 Lithobates capito +2 2 0 [30]
CPb FLPIVGRLISGIL-NH2 13 Lithobates capito 0 0 0 [30]
1DRa HFLGTLVNLAKKIL-NH2 14 Rana aurora draytonii +2 2 0 [31]
1DRb NFLGTLVNLAKKIL-NH2 14 Rana aurora draytonii +2 2 0 [31]
1DRc FLPIIASVLSSLL-NH2 13 Rana aurora draytonii 0 0 0 [31]
1DYa FIGPIISALASLFG- NH2 14 Rana dybowskii 0 0 0 [32]
1Ec FLPIIAGLLSKLF-NH2 13 Rana esculenta +1 1 0 [33]
1Ee FLPVIAGVLSKLF-NH2 13 Pelophylax kl. esculentus +1 1 0 [34]
1Ga SILPTIVSFLSKVF-NH2 14 Rana grylio +1 1 0 [35]
1Gb SILPTIVSFLSKFL-NH2 14 Rana grylio +1 1 0 [35]
1Gc SILPTIVSFLTKFL-NH2 14 Rana grylio +1 1 0 [35]
1Gd FILPLIASFLSKFL-NH2 14 Rana grylio +1 1 0 [35]
GH FLPLLFGAISHLL-NH2 13 Hylarana guentheri 0 0 0 [36]
Gua FLQHIIGALSHIF-NH2 13 Hylarana guntheri 0 0 0 [37]
Gub FLPLLFGAISHIL-NH2 13 Hylarana guntheri +1 1 0 [37]
Guc FFPLIFGALSSILPKIL-NH2 17 Hylarana guntheri +1 1 0 [37]























































Temporin Amino acid sequence
No.
amino







HN1 AILTTLANWARKFL-NH2 14 Odorrana hainanensis +2 2 0 [39]
HN2 NILNTIINLAKKIL-NH2 14 Odorrana hainanensis +2 2 0 [39]
1Ja ILPLVGNLLNDLL-NH2 13 Rana japonica -1 0 1 [40]
1La VLPLISMALGKLL-NH2 13 Rana luteiventris +1 1 0 [41]
1Lb NFLGTLINLAKKIM-NH2 14 Rana luteiventris +2 2 0 [41]
1Lc FLPILINLIHKGLL-NH2 14 Rana luteiventris +2 2 0 [41]
LK1 FFPLLFGALSSMMPKLF-NH2 17 Limnonectes kuhlii +1 1 0 [42]
LTa FFPLVLGALGSILPKIF-NH2 17 Hylarana latouchii +1 1 0 [43]
LTb FIITGLVRGLTKLF-NH2 14 Hylarana latouchii +2 2 0 [43]
LTc SLSRFLSFLKIVYPPAF-NH2 17 Hylarana latouchii +2 2 0 [43]
LTe FLAGLIGGLAKML-NH2 13 Hylarana latouchii +1 1 0 [44]
LT1 FLPGLIAGIAKML-NH2 13 Hylarana latouchii +1 1 0 [45]
LT2 FLPIALKALGSIFPKIL-NH2 17 Hylarana latouchii +2 2 0 [45]
1M FLPIVGKLLSGLL-NH2 13 Rana muscosa +1 1 0 [46]
1Oa FLPLLASLFSRLL-NH2 13 Rana ornativentris +1 1 0 [47]
1Ob FLPLIGKILGTIL-NH2 13 Rana ornativentris +1 1 0 [47]
1Oc FLPLLASLFSRLF-NH2 13 Rana ornativentris +1 1 0 [47]
1Od FLPLLASLFSGLF-NH2 13 Rana ornativentris 0 0 0 [47]
1Oe ILPLLGNLLNGLL-NH2 13 Rana ornativentris 0 0 0 [48]
1Of SLLLKGLASIAKLF-NH2 14 Rana ornativentris +1 1 0 [48]
1Og FLSSLLSKVVSLFT-NH2 14 Rana ornativentris +1 1 0 [48]
1OLa FLPFLKSILGKIL-NH2 13 Rana okaloosae +2 2 0 [49]
1OLb FLPFFASLLGKLL-NH2 13 Rana okaloosae +1 1 0 [49]
1P FLPIVGKLLSGLL-NH2 13 Rana pipiens +1 1 0 [41]
1PLa FLPLVGKILSGLI-NH2 13 Rana palustris +1 1 0 [50]
1PRa ILPILGNLLNGLL-NH2 13 Rana pirica 0 0 0 [51]
1PRb ILPILGNLLNSLL-NH2 13 Rana pirica 0 0 0 [51]
PRa FLPILGNLLSGLL-NH2 13 Rana pretiosa 0 0 0 [52]
PRb FLPIITNLLGKLL-NH2 13 Rana pretiosa +1 1 0 [52]
PRc NFLDTLINLAKKFI-NH2 14 Rana pretiosa +1 1 1 [52]
PTa FFGSVLKLIPKIL-NH2 13 Hylarana picturata +2 2 0 [53]
Ra FLKPLFNAALKLLP-NH2 14 Rana ridibunda +2 2 0 [54]
Rb FLPVLAGVLSRA-NH2 12 Rana ridibunda +1 1 0 [54]
1Re FLPGLLAGLL-NH2 10 Pelophylax kl. esculentus 0 0 0 [34]
RN1 FLPLVLGALSGILPKIL-NH2 17 Rana nigrovittata +1 1 0 [55]
RN2 FFPLLFGALSSLLPKLF-NH2 17 Rana nigrovittata +1 1 0 [55]
RN3 FFPLLFGALSSHLPKLF-NH2 17 Rana nigrovittata +2 2 0 [55]
1Sa FLSGIVGMLGKLF-NH2 13 Pelophylax saharica +1 1 0 [56]
1Sb FLPIVTNLLSGLI-NH2 13 Pelophylax saharica 0 0 0 [56]
1Sc FLSHIAGFLSNLF-NH2 13 Pelophylax saharica +1 1 0 [56]
1SKa FLPVILPVIGKLLNGIL-NH2 17 Rana sakuraii +1 1 0 [57]
1SKb FLPVILPVIGKLLSGIL-NH2 17 Rana sakuraii +1 1 0 [57]
1SPa FLSAITSILGKFF-NH2 13 Rana septentrionalis +1 1 0 [58]
1SPb FLSAITSLLGKLL-NH2 13 Rana septentrionalis +1 1 0 [58]
1SPc FLSAITSILGKLF-NH2 13 Rana septentrionalis +1 1 0 [58]
SHa FLSGIVGMLGKLF-NH2 13 Pelophylax saharica. +1 1 0 [59]
SHb FLPIVTNLSGLL-NH2 12 Pelophylax saharica. 0 0 0 [59]
SHc FLSHIAGFLSNLF-NH2 13 Pelophylax saharica +1 1 0 [59]
SHd FLPAALAGIGGILGKLF-NH2 17 Pelophylax saharica +1 1 0 [60]
SHf FFFLSRIF-NH2 8 Pelophylax saharica +1 1 0 [23]
SN1 FFPFLLGALGSLLPKIF-NH2 17 Hylarana spinulosa +1 1 0 [61]
SN2 FITGLIGGLMKAL-NH2 13 Hylarana spinulosa +1 1 0 [61]
SN3 FISGLIGGLMKAL-NH2 13 Hylarana spinulosa +1 1 0 [61]
SN4 FITGLISGLMKAL-NH2 13 Hylarana spinulosa +1 1 0 [61]
SN5 FFPLVLGALGSILPKIF-NH2 17 Hylarana spinulosa +1 1 0 [61]
1TGa FLPILGKLLSGIL-NH2 13 Rana tagoi +1 1 0 [62]
1TGb AVDLAKIANKVLSSLF-NH2 16 Rana tagoi +1 2 1 [63]
1TGc FLPVILPVIGKLLSGIL-NH2 17 Rana tagoi +1 1 0 [63]
1TSa FLGALAKIISGIF-NH2 13 Rana tsushimensis +1 1 0 [64]
1TSb FLPLLGNLLNGLL-NH2 13 Rana tsushimensis 0 0 0 [64]
1TSc FLPLLGNLLRGLL-NH2 13 Rana tsushimensis +1 1 0 [64]
1TSd FLPLLASLIGGML-NH2 13 Rana tsushimensis 0 0 0 [64]






















































new branching unit 3-N,N-di(3-aminopropyl)amino propa-
noic acid (DAPPA), which allows building of the parallelly
symmetric a-helical structures. These analogues were tested
against S. aureus (gram-positive) and Escherichia coli
(gram-negative). Both TA and TAd completely inhibited the
growth of S. aureus, whereas TAc did not show any inhibi-
tory activity. The TAd displayed antibacterial effect against
E. coli, whereas monomeric TA did not show any activity at
concentration higher than 20 mM. The results indicated that
these structural modifications improved the antibacterial
properties of TA especially because of the increase of the net
charge of the peptide from +2 to +4 [77].
The TA enantiomer (with d-amino acids, d-TA) also showed
good antimicrobial activity against bacteria, and the replace-
ment of some amino acids improved the activity [68]. In an-
other study, the d-TA and the reverse TA sequence (Rev-TA)
were compared with TA. The TA induced monocyte migration,
while both TA analogues did not, suggesting that TA-induced
monocyte migration is based on a chiral interaction [78].
Other studies performed with temporin A, B, D, and H have
shown that in Lysogeny broth (LB) medium, temporins D and H
were completely inactive, whereas TA and TB showed a higher
activity against the gram-positive bacterial strain than against
the gram-negative one. In addition, TA and TB also caused total
reduction in colony-forming units of S. aureus [67].
In addition, Magnoni et al. [79] found an anti-Leishmania
activity at micromolar concentrations for TA and TB with no
cytolytic activity against human erythrocytes. The ability of
temporins to kill Leishmania amastigotes was assayed by inhi-
bition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction test [79]. Both temporins preserved
their activity against the mammalian intracellular form of the
parasite.
They also investigated whether the mode of action of tem-
porins against Leishmania amastigotes was similar to that
found for promastigotes. They found that TA and TB could
induce the permeation of the amastigote membrane, although
TB was more active than TA. In addition, both temporins in-
duced the permeation of the membrane of amastigotes similarly
to the promastigotes [67]. Finally, experiments with TA found
that this peptide not only is suitable as an antimicrobial peptide
but also can be administrated topically in mice wounds together
with antibiotic agents, generating a significant bacterial growth
inhibition and acceleration of wound repair process [80].
To improve AMPs administration, new polymeric carriers
can be used as highly controlled release devices. Piotrowska
et al. [81] chose the peptides citropin 1.1 (CIT) and TA for
their experiments. They found that the release rate of the
active pharmaceutic ingredients (APIs) was strongly depen-
dent on the API characteristics and the matrix microstructure.
They investigated the effect of the carrier polymer micro-
structure in both peptide kinetics release in vitro. Results
suggested these polymeric devices as good therapeutic carrier
candidates and TA as a prospective therapeutic option [81].
Table 1. (Continued)
Temporin Amino acid sequence
No.
amino







1Va FLSSIGKILGNLL-NH2 13 Rana virgatipes +1 1 0 [66]
1Vb FLSIIAKVLGSLF-NH2 13 Rana virgatipes +1 1 0 [66]
1Vc FLPLVTMLLGKLF-NH2 13 Rana virgatipes +1 1 0 [66]
Wa FISKIASLGAGVLX-NH2 14 Lithobates warszewitschii +1 1 0 [30]
The table shows the sequence, number of amino acids, positive, negative, and net charge of each temporin. Those amino acids in red
(K, H, and R) correspond to basic amino acids, and those in green (D, E) correspond to acidic amino acids.
FIG. 1. Number of temporins with +1, +2, -1, and 0
charge. Most of the temporins (85 peptides) present +1
charge, 24 temporins have no net charge, 18 have +2, and
only three temporins have negative charge.
FIG. 2. Antimicrobial and hemolytic activity of the tempor-
ins. From 85 temporins analyzed against gram-positive bacteria,
83 showed positive activity; from 79 temporins analyzed
against gram-negative bacteria, 45 showed positive activity; and
32 of 65 temporins showed good antimicrobial activity against
fungi. From 57 temporins, 39 presented hemolytic activity.




















































The TA applications were not limited to antimicrobial
activities. Musale et al. [82] found that TA, together with
temporin F (TF) and G (TG), produced concentration-
dependent stimulation of insulin release from BRIN-BD11
rat clonal b-cells at concentrations ‡1 nM, without cytotox-
icity at concentrations up to 3 mcM. In these experiments, TA
was the most effective. Also, TA together with TF protected
BRIN-BD11 cells against cytokine-induced apoptosis [82].
Temporin B
Malgieri et al. [83] elucidated mechanisms of action of
temporin B (TB, LLPIVGNLLKSLL-NH2) synthetic deriv-
atives. Some of these peptide derivatives showed gram-
negative and gram-positive inhibition with no hemolytic
activity. Marcocci et al. [84] recently demonstrated for the
first time the in vitro anti-herpes simplex virus type 1 (HSV-1)
activity of TB. A significant antiviral activity was observed
in a pre-incubation of HSV-1 with 20 mcg/mL of TB. When
TB was added to HSV-1-infected cells, viral titer was sig-
nificantly reduced. Moreover, the highest inhibition was
obtained by pre-incubation of HSV-1 with the peptide for 1 h
at 37C, demonstrating its viricidal activity [84].
In addiion, a d form of TB has been used together with TB
to test the antimicrobial activity compared with CAMEL
peptide (CA(1–7)M(2–9)NH2). This last peptide is a 15-
residue hybrid amide peptide with seven amino acids that are
derived from the sequence of cecropin A (silkmoth Hyalo-
phora cecropia larvae) and eight amino acids from the se-
quence of melittin (honey-bee venom). The results showed
that the antimicrobial activity of the d form of temporin B
was detected after 30 min, and no activity was detected after
24, 48, and 72 h. The d isomer of temporin B was inactivated
more slowly in feces than the l isomer [85].
Another study evaluated the role of each amino acid on the
peptide activity of TB. Avitable et al. [86] performed a complete
Ala scanning of TB by substituting one or two amino acids with
alanine residues to obtain a series of TB analogues. Best results
were obtained with the analogue TB_KKG6A (KKLLPI-
VANLLKSLLNH2) that showed antimicrobial activity against
gram-positive and gram-negative bacteria at a concentration of
5 mcM [86]. This peptide, together with other analogues, was
used to find antimicrobial activity against Pseudomonas aeru-
ginosa. One of the TB analogues, TBKKG6A, exhibited strong
antimicrobial activity [87].
In addition, enhancing the hydrophobicity of the N-terminus
and the cationicity of the C-terminus in TB improves its
membrane activity and potency against both gram-negative
and gram-positive bacteria. In contrast, enhancing the catio-
nicity of the N-terminus abrogates its ability to trigger channel
conductance and renders it ineffective against S. aureus while
nevertheless enhancing its potency against E. coli [70].
In other studies concerning infection of human keratino-
cytes with S. aureus, TB and TA were used to improve the
treatment against this bacterium. Results showed that TB
killed ATCC-derived (ATCC: American Type Culture Col-
lection) and multi-drug–resistant clinical isolates of S. aureus
within infected human keratinocytes at a non-toxic concen-
tration of 16 mcM within 2 h and without injuring the host
cells, whereas a weaker effect was displayed by TA. With the
combination of antibacterial and wound-healing activities,
TA and TB seemed to act as multi-functional mediators of
innate immunity in humans [88]. In addition, TB acted syn-
ergistically with other reagents, such as cysteine and ethy-
lenediaminetetraacetic acid. These combinations improved
the antimicrobial activity of the temporin against S. epi-
dermidis biofilms [89].
Lipopolysaccharides (LPS) have been important in tem-
porin studies because of the interaction between them and the
fact that LPS are the major structural component of the outer
membrane of gram-negative bacteria. The LPS usually are
used as models for molecular dynamics to study the antimi-
crobial activity of the temporins—for example, TB [90].
Also, LPS have been used in different studies using temporin
L (see below).
These results make TB a promising alternative as an an-
tibacterial drug, although its toxicity still needs more re-
search, especially in mammalian cells. It is well known that
AMPs represent promising therapeutic agents against bac-
terial and fungal pathogens, although one of their principal
limitations is their cytotoxicity to eukaryotic cells and
erythrocytes [91,92]. The TB is not an exception. Some
alternatives to solve this problem have been proposed to
improve its pharmaceutic development, such as TB encap-
sulation into chitosan nanoparticles [93].
Temporin L
Temporin L (TL, FVQWFSKFLGRIL-NH2) has a large
antimicrobial activity, especially for fungal pathogens and
gram-negative bacteria, while temporins are generally
gram-positive inhibitors. This temporin has potential anti-
endotoxin properties and can strongly bind to purified E. coli
LPS and interfere with its biologic activities in two rat models
of gram-negative septic shock, protecting the animals against
lethal endotoxemia [72].
The mechanism of action of TL (together with TB) to
penetrate the phospholipid bilayer has been studied in dif-
ferent ways, and it seems the peptides penetrate the mem-
brane through the formation of fibrillar protrusions [94]. The
interaction of TL (and TB) with bacteria membrane has also
been studied using spectroscopic techniques [95]. This pep-
tide displays the highest antimicrobial potency among tem-
porins tested to date and has strong affinity for lipid
membranes and for the LPS component of the gram-negative
outer membrane [72].
As stated earlier, LPS are important in temporin studies.
The temporins not only interact with LPS but also can exhibit
a synergistic effect when more than two temporins are
combined [96,97]. As found for TA, TL also can be admin-
istrated intraperitoneally with piperacillin and imipenem, two
b-lactam antibiotic agents, and play a strong synergistic ac-
tivity against some E. coli strains [72].
In a study using more than 20 different bacteria strains,
antimicrobial activity of TL and TB was analyzed. The TL
showed at least 10-fold higher activity against all micro-
organisms tested than TB. In contrast with other temporins,
which are known to be active against gram-positive bacteria,
TL also displayed very good activity against gram-negative
bacterial strains such as E. coli and P. aeruginosa. Results
also showed an important cytotoxic activity to three different
human tumor cell lines (Hut-78, K-562, and U-937). Another
study of the interaction of TL with liposomes of differ-
ent lipid compositions revealed that the peptide causes




















































perturbation of bilayer integrity of both neutral and nega-
tively charged membranes. These characteristics make TL a
special AMP for many of the human pathogens [98].
Another work reported the mode of action of TL on E. coli
D21 cells. The results showed that the peptide increased the
permeability of the bacterial inner membrane in a dose-
dependent manner without destroying the integrity of the cell
and preserving DNA integrity [99]. Also, together with TB,
its mechanism of action into cell membrane has been studied
in different ways, with the aim to understand its insertion into
lipid monolayers as well as the effects on the structural dy-
namics of liposomal bilayers [100].
Finally, Saviello et al. [101] developed new analogues with
potential biologic activities named Pro3-TL and Gln3-TA, in
which Pro3 from TA was changed by a Gln, and the Gln3 from
TL was changed by a Pro. They performed a detailed nuclear
magnetic resonance analysis of the new analogues in sodium
dodecyl sulfate (SDS) and dodecylphosphocholine micelles,
which mimic bacterial and mammalian membranes, respec-
tively. Their results showed that Pro3-TL exhibited an in-
creased antimicrobial activity toward gram-positive and yeast
cells, with a hemolytic activity 2–5-fold lower than that of the
natural TL, over a concentration range of 3–12 mcM. Gln3-TA
also exhibited promising antimicrobial activity, but its hemo-
lytic activity became significantly stronger compared with that
of parent peptide TA (up to 10-fold higher).
Because the hemolytic activity of TL was associated with
its strong propensity for helical structure at the N-terminus,
authors replaced a proline residue in position 3 with the aim
of inducing a turn structure in the derivative Pro3-TL. In the
case of Gln3-TA, according to the authors, replacement of
the native proline residue with a glutamine should lead to
increased helical content at the N-terminus. Their results
confirmed the existence of N-terminal turn structures in the
Pro3-TL and the existence of R-helix in N-terminus region
of Gln3-TA. This confirms that helical content controls the
hemolytic effect, while it is irrelevant to the antimicrobial
activity of the temporins [101].
Other Temporins
Since the discovery of temporins by Simmaco et al. [10],
several groups of researchers isolated different peptides from
various species of frogs that were included as members of this
family (Table 1). Both S. aureus and E. coli were chosen as
model micro-organisms for the analysis of the antimicrobial
activity against gram-positive and gram-negative bacteria,
respectively. In addition, C. albicans was the main model
organism for the analysis of the anti-micotic activity of these
peptides. Table 2 resumes the antimicrobial activity of the
temporins discovered until today.
Although antimicrobial activity of many temporins has not
been analyzed yet, there are common properties between the
peptides. For example, most of the temporins with tested
antimicrobial activity have a +1 charge (Fig. 1), most tem-
porins with antimicrobial activity against gram-negative
bacteria already have activity against gram-positive bacteria,
except for 1PRb from R. pirica [51] and the 1CS temporin
family, from the skin of R. cascadae [29]. The two temporins
without net charge (temporin GH and 1Od) have no acidic or
basic amino acids and are active against gram-positive bac-
teria [36,48]. Those temporins with +2 net charge are only
active against gram-positive bacteria, except for temporin L,
CPa, and 1DRa, which are also active against gram-negative
and fungi [30,31,95,102].
Some of these temporins were chosen for different anti-
microbial studies. For example, temporins SHa-c (TSHa-c)
was assayed against bacteria, filamentous fungi, and yeasts.
The results reported by Abbassi et al. [59] showed that SHa
was active against most of the tested micro-organisms at
micro-molar concentrations; SHc was inactive against gram-
negative bacteria but effectively inhibited the proliferation of
yeasts and fungi. On the other hand, temporin TSHb was
virtually inactive against all the tested micro-organisms [59].
The TSHa was also selected to design hybrid silylated
biomolecules based on TSHa amphipathic helical antimi-
crobial sequence and titanium surfaces for the attachment of
the peptides. With the design of five TSHa analogs, Masurier
et al. [103] showed that the antibacterial activity of the
temporin-grafted surfaces was greater on the E. coli strain
than on the S. epidermidis strain, regardless of the anchoring
position. Wang et al. [22] isolated a temporin family (named
AL) from the skin secretion of the Chinese frog Amolops
loloensis with antimicrobial activity against gram-positive,
gram-negative bacteria and fungus, as TSHa [22].
Urban et al. [102] chose two different temporins (tem-
porin 1DRa from R. aurora draytonii and temporin-1Va
from R. virgatipes) to analyze the growth inhibitory activity
of synthetic replicates of these peptides against a range
of reference strains and clinical isolates of gram-positive and
gram-negative [66,104]. Temporin 1DRa was the only pep-
tide to show inhibitory activity. It also showed relatively
low hemolytic activity against human erythrocytes, which
could represent a potential candidate for drug development,
particularly for topical therapy of infected surface lesions
[102].
Conlon et al. [104] analyzed the toxicity against mam-
malian cells of temporin 1DRa modified by different amino
acid substitutions by replacing different amino acid residues
by a-aminoisobutyric acid (Aib). The Aib substitutions could
induce a b-turn in small peptides but, in larger peptides, the
residue could either promote the formation of an a-helix or
stabilize an existing helical conformation.
This study was focused not only on the effect of these sub-
stitutions but also on the effect of the modification of the dis-
solution buffer. Regarding the Leu9, Ile13, Leu14 substitutions,
the peptide presented lower cytolytic activity against mam-
malian cells, retaining the antimicrobial activity over the micro-
organisms tested. Substitution of the Gly4, Thr5, Asn8, and
Ala10 residues by Aib produced analogs that showed increased
antimicrobial potencies against the gram-positive bacteria S.
aureus (fourfold for Aib4 and Aib8, twofold for Aib5 and Aib10)
and against C. albicans, but only the Aib8 analog showed in-
creased potency (twofold) against the gram-negative bacteria
E. coli [104].
Twelve analogues of temporin 1DRa were also tested as
alternatives to manage infections by multi-drug resistant
pathogens in skin infection. Results showed that some of
these peptides were promising candidates for further devel-
opment into therapeutic agents for topical treatment of skin
infections. Two other temporins (temporins HN1-2, THN1-2)
were tested against 12 different species of micro-organisms.
Both peptides proved to be effective against all the micro-
organisms tested [39,105].




















































Table 2. Antimicrobial and Hemolytic Activities of Temporins
Antimicrobial activity
Temporin Amino acid sequence Gram + Gram - Fungi
Hemolytic
activity Reference
A FLPLIGRVLSGIL-NH2 2.3 mcM 11.9 mcM 3.4 mcM >120 mcM [10]
B LLPIVGNLLKSLL-NH2 6.0 mcM 21 mcM 4.0 mcM >120 mcM [10]
L FVQWFSKFLGRIL-NH2 3.0 mcM 12.0 mcM 12.0 mcM 94 mcM [10]
1ARa FLPIVGRLISGLL-NH2 15.0 mcM 125.0 mcM NA NA [19]
1AUa PLPIIGQLLSGLL-NH2 >80 mcM ND ND NA [20]
ALa FLPIVGKLLSGLSGLL-NH2 2.0 mcM 3.0 mcM 6.5 mcM ND [21]
ALd FLPIAGKLLSGLSGLL-NH2 >1 mcM >1 mcM >1 mcM 7.5 mM [22]
ALe FFPIVGKLLFGLSGLL-NH2 >1 mcM >1 mcM >1 mcM 5.8 mM [22]
ALf FFPIVGKLLSGLSGLL-NH2 1.5 mcM 1.5 mcM 1.5 mcM 4.2 mcM [22]
ALg FFPIVGKLLFGLFGLL-NH2 1.4 mcM 2.8 mcM >1 mcM 8.9 mcM [22]
ALh FLPIVGKLLSGLSGLS-NH2 1.6 mcM 3.1 mcM 1.6 mcM 8.1 mcM [22]
ALi FFPIVGKLLSGLL-NH2 5.3 mcM 5.3 mcM 3.5 mcM 15.0 mcM [22]
ALj FFPIVGKLLFGLL-NH2 5.1 mcM 10.2 mcM 3.4 mcM 13.0 mcM [22]
ALk FFPIVGKLLS-NH2 13.4 mcM 26.8 mcM 13.4 mcM 22.3 mcM [22]
1BYa FLPIIAKVLSGLL-NH2 15 mcM NA NA NA [23]
1Cb FLPLFASLIGKLL-NH2 140 mcM NA NA NA [24]
1Cd FLPFLASLLSKVL-NH2 80 mcM NA NA NA [24]
1Ce FLPFLATLLSKVL-NH2 >100 mcM NA NA NA [24]
1CEa FVDLKKIANIINSIF-NH2 14.4 mcM >100 mcM ND NA [25]
1CEb ILPILSLIGGLLGK-NH2 41 mcM >100 mcM ND NA [25]
CDYb ILPILAPLIGGLL-NH2 >100 mcM >100 mcM ND 180 mcM [26]
CG1 FLPFVGNLLKGLL-NH2 9 mcM NA NA NA [28]
CG2 FFPIVGKLLSGLF-NH2 150 mcM NA NA NA [28]
CG3 FLPIVGKLLSGLF-NH2 150 mcM NA NA NA [28]
CG4 FLPILGNLLNGLL-NH2 NA NA NA NA [28]
CG5 FLPFVGNLLNGLL-NH2 NA NA NA NA [28]
1CSa FLPIVGKLLSGLL-NH2 8 mcM 128 mcM ND 75 mcM [29]
1CSb FLPIIGKLLSGLL-NH2 8 mcM 128 mcM ND 95 mcM [29]
1CSc FLPLVTGLLSGLL-NH2 64 mcM >128 mcM ND NA [29]
1CSd NFLGTLVNLAKKIL-NH2 16 mcM 64 mcM ND 50 mcM [29]
CPa IPPFIKKVLTTVF-NH2 2.3 mcM 2.3 mcM +(<20 mcM) NA [30]
CPb FLPIVGRLISGIL-NH2 ND ND ND ND [30]
1DRa HFLGTLVNLAKKIL-NH2 5 mcM 20 mcM 40 mcM 70 mcM [31]
1DRb NFLGTLVNLAKKIL-NH2 20 mcM 40 mcM 80 mcM 65 mcM [31]
1DYa FIGPIISALASLFG- NH2 >60 mcM >60 mcM ND ND [32]
1Ec FLPIIAGLLSKLF-NH2 8 mcM NA ND ND [33]
1Ee FLPVIAGVLSKLF-NH2 10 mcM 40 mcM NA ND [34]
1Gb SILPTIVSFLSKFL-NH2 24 mcM NA NA ND [35]
1Gc SILPTIVSFLTKFL-NH2 25 mcM NA NA ND [35]
1Gd FILPLIASFLSKFL-NH2 12 mcM NA NA ND [35]
GH FLPLLFGAISHLL-NH2 44.3 mcM NA NA ND [36]
HN1 AILTTLANWARKFL-NH2 37.5 mcM NA 75 mcM 75 mcM [39]
HN2 NILNTIINLAKKIL-NH2 4.8 mcM NA 9.5 mcM NA [39]
1La VLPLISMALGKLL-NH2 60 mcM ND ND ND [41]
1Lb NFLGTLINLAKKIM-NH2 48 mcM NA NA ND [41]
1Lc FLPILINLIHKGLL-NH2 125 mcM NA NA ND [41]
LK1 FFPLLFGALSSMMPKLF-NH2 1.3 mcM 15 mcM 2.6 mcM 51 mcM [42]
LTa FFPLVLGALGSILPKIF-NH2 11 mcM ND NA 5 mcM [43]
LTb FIITGLVRGLTKLF-NH2 8 mcM ND NA 127 mcM [43]
LTc SLSRFLSFLKIVYPPAF-NH2 25 mcM ND NA 100.8 mcM [43]
LTe FLAGLIGGLAKML-NH2 9.5 mcM NA NA 40 mcM [44]
LT1 FLPGLIAGIAKML-NH2 9.3 mcM ND NA 74.5 mcM [45]
LT2 FLPIALKALGSIFPKIL-NH2 7 mcM ND NA 109 mcM [45]
1Oa FLPLLASLFSRLL-NH2 2.0 mcM 70 mcM ND ND [47]
1Ob FLPLIGKILGTIL-NH2 5 mcM 140 mcM NA ND [47]
1Oc FLPLLASLFSRLF-NH2 2 mcM NA ND ND [47]
1Od FLPLLASLFSGLF-NH2 13 mcM NA ND ND [47]
1Oe ILPLLGNLLNGLL-NH2 NA NA NA ND [48]
1P FLPIVGKLLSGLL-NH2 110 mcM ND ND ND [41]
1PRa ILPILGNLLNGLL-NH2 >100 mcM >100 mcM >100 mcM NA [51]
1PRb ILPILGNLLNSLL-NH2 >100 mcM >100 mcM >100 mcM NA [51]
PRa FLPILGNLLSGLL-NH2 50 mcM >100 mcM ND ND [52]






















































Temporin CPa from Lithobates capito has an atypical se-
quence IPPFIKKVLTTVF-NH2, and unlike most of the
temporins, it showed atypical growth-inhibitory activity
having greater potency against E. coli and C. albicans than
against S. aureus [30]. Yang et al. [28] found a group of
peptides (temporins TC 1-5, TCG1-5) with antimicrobial ac-
tivity against gram-positive bacteria at low concentrations
compared to other AMPs. Abbassi et al. [56] isolated three
peptides, named temporins 1Sa-c from the skin of the Sahara
frog Pelophylax (Rana) saharica. As temporin 1G, 1Sa was
effective against gram-positivebacteria [56].
Some temporins have low or no antimicrobial activity,
although they present conserved features to the active pep-
tides (13 amino acids, one basic amino acid, +1 charge). For
example, temporins SPa-c showed very low antimicrobial
activity, with positive response only for S. aureus [58].
Temporins 1PRa-b, Ska-b, and LT also showed low antimi-
crobial activity with gram-positive bacteria, very low or no
activity with gram-negative bacteria, and no effectiveness
against yeasts [35–37,41,43,51,57,62,105,106].
Finally, new temporins were found in different researches.
The first, temporin Wa (TWa) was found in Lithobates
warszewitschii, and it was not possible to establish the
complete amino acid sequence (FISKIASLGAGVLX-NH2,
Table 1). A second temporin found in the skin secretion of R.
muscosa (1M) was isolated as free acid form. This was an
unexpected finding because the presence of such peptides in
frog skin secretions has not been reported previously. Au-
thors determined that it is unclear whether the peptide is an
authentic secretion product or is derived by artifactual hy-
drolysis during the extraction and purification process. Ex-
periments with a pathogenic chytrid fungus showed that this
temporin inhibited chytrids at concentrations above 6.25 mM
with a minimum inhibitory concentration (MIC) of 100 mM
against zoospores [46]. No other antimicrobial activity has
been tested yet.
A third one, temporin LK1 (TLK1), was found in Limno-
nectes kuhlii frogs. This peptide of 17 amino acids showed
antimicrobial activity against gram-positive and gram-negative
bacteria and fungi [42]. This temporin was also selected for
an antimicrobial activity analysis of five structural analogs.
These peptides were prepared by substitution of achiral gly-
cine residue of TLK1 with d-alanine, l-phenylglycine, and
l-naphthylalanine, respectively. Analogs 2–4 showed activity
against P. aeruginosa and S. aureus [106].
Pharmacologic Application
Antibiotic agents are essential in medicine for the control
of pathogens in human and other species. Their abuse and
misuse, however, have increased the number of resistant
micro-organisms. This entails the need to develop new and
better alternatives for multi-drug–resistant bacteria [107,108].
Peptides are molecules with a simple chemical structure that
can be synthesized at low-cost on a large scale. In addition,
it is feasible to chemically modify them to improve their




Temporin Amino acid sequence Gram + Gram - Fungi
Hemolytic
activity Reference
PRc NFLDTLINLAKKFI-NH2 50 mcM >100 mcM >50 mcM 80 mcM [52]
Ra FLKPLFNAALKLLP-NH2 22.1 mcM 15.3 mcM ND ND [54]
Rb FLPVLAGVLSRA-NH2 28.4 mcM 27.8 mcM ND ND [54]
1Re FLPGLLAGLL-NH2 60 mcM NA NA ND [34]
RN1 FLPLVLGALSGILPKIL-NH2 2.7 mcM NA 4.7 mcM ND [55]
RN3 FFPLLFGALSSHLPKLF-NH2 3.9 mcM 7.8 mcM 1.9 mcM ND [55]
1Sa FLSGIVGMLGKLF-NH2 3 mcM 10 mcM 16 mcM 25mM [56]
1Sb FLPIVTNLLSGLI-NH2 58 mcM NA >116 mcM >116mM [56]
1Sc FLSHIAGFLSNLF-NH2 10 mcM >80 mcM 20 mcM >80 mcM [56]
1SKa FLPVILPVIGKLLNGIL-NH2 25 mcM >50 mcM >50 mcM ND [57]
1SKb FLPVILPVIGKLLSGIL-NH2 25 mcM >50 mcM ND ND [57]
1SPb FLSAITSLLGKLL-NH2 6 mcM ND ND 60 mcM [58]
SHa FLSGIVGMLGKLF-NH2 3 mcM 10 mcM 16 mcM 25 mcM [59]
SHb FLPIVTNLSGLL-NH2 58 mcM >116 mcM >116 mcM >116 mcM [59]
SHc FLSHIAGFLSNLF-NH2 10 mcM NA 20 mcM >80 mcM [59]
SHd FLPAALAGIGGILGKLF-NH2 6.5 mcM >25 mcM 100 mcM 44 mcM [59]
SHf FFFLSRIF-NH2 12.5 mcM >80 mcM 50 mcM 200 mcM [23]
SN1 FFPFLLGALGSLLPKIF-NH2 12.5 mcM NA NA ND [61]
SN2 FITGLIGGLMKAL-NH2 100 mcM NA NA ND [61]
SN3 FISGLIGGLMKAL-NH2 25 mcM NA NA ND [61]
SN4 FITGLISGLMKAL-NH2 12.5 mcM NA NA ND [61]
1Va FLSSIGKILGNLL-NH2 20 mcM 40 mcM NA 120 mcM [66]
1Vb FLSIIAKVLGSLF-NH2 10 mcM NA NA 30 mcM [66]
1Vc FLPLVTMLLGKLF-NH2 10 mcM NA NA 30 mcM [66]
The criteria were selected according to the bibliography: High (minimum inhibitory concentrations [MICs] <5 mcM); positive MICs <50
mcM); low (MICs between 50 mcM and 150 mcM); NA (not active up to 150 mcM); ND (no data). In all cases, the micro-organisms
selected for the information were Staphylococcus aureus, Escherichia coli, and Candida albicans.




















































These properties make them good candidates for new drug
developments, especially those with synergistic effect when
more than one peptide is combined. This can be exemplified
by the combinations of TA, TB, and TL in studies against E.
coli strains. As a consequence of the antibiotic therapy of
gram-negative bacterial infections, LPS or endotoxins can be
released. The use of compounds capable of sequestering LPS
has been suggested to avoid sepsis. These three temporins
showed a synergistic effect on LPS sequester [109,110]. On
the other hand, TL avoided the LPS-induced self-assembly
of TA and TB. For this reason, it has been suggested that
AMPs in combination with other drugs, could be good can-
didates for antibacterial or anti-endotoxin treatment, avoid-
ing the generation of bacterial resistance to the therapy
[96,111,112]. These temporins could be used as potential
drugs and represent promising alternatives to supply antibi-
otic agents.
In addition, temporins B and L can penetrate lipid mono-
layers and generate molecular interaction with different
liposomes, which could be an alternative through the en-
capsulation of these peptides for drug administration [100].
Temporin 1DRa also could represent a potential candidate for
a drug, as was explained earlier [102,105,113].
Today, the new challenge is to load the peptides into
polymeric drug delivery systems. Recently, Piotrowska et al.
[81] developed new polymeric carriers to control the release
of TA and other AMPs to improve the use of new therapeutic
candidates for the management of local infections.
Antifungal resistance has become a challenge for new drug
design. Currently there are only five therapeutic alternatives
for the management of fungal infections (azoles, echino-
candins, polyenes, allylamines, and pyrimidine analogs).
Most antifungal agents show high toxicity and undesirable
side effects that limit their use in medicine. Patients with
immunodeficiencies are more likely to have fungal infections
develop. The use of antifungal agents as prophylactic agents,
however, has favored the emergence of drug resistances in
species of Candida and Cryptococcus as well as other path-
ogenic fungi [113,114].
In addition to the design strategies for the production of
more efficient drugs against pathogens with antibiotic resis-
tance, the use of nanotechnology has been proposed for the
development of new administration systems that are expected
to spread widely and rapidly. In this way, the reduction of
toxicity and side effects of current dugs can be achieved
[115]. Combination of nanotechnology and AMPs in differ-
ent antimicrobial treatments could be a promising alternative
for resistance pathogens. Therefore, drugs must be of low
cost so that lower income groups can easily get a treatment
with new novel drug molecules, which can help to fight
against drug resistance [108].
Conclusion
Although temporins have been gaining importance in an-
timicrobial studies, many of them have not been fully ana-
lyzed yet. Most of these peptides have shown interesting and
promising properties, together with the advantages explained
in this article. This makes this family a potential alternative
for pharmacology and biotechnology industries, for the re-
search of new drugs with more effective administration
methods and minor injuries.
Although recent researches with the most studied tem-
porins (TA, TB, and TL) showed the potential of these small
peptides, the temporin family is still an unexplored AMP
group in pharmacology industries. Some recently discovered
temporins do not present photosensitive amino acids (as
cysteine or tryptophan), which is an advantage for drug de-
livery, because the molecular and chemical stability of the
peptides allow an efficient and secure administration. Al-
though TL showed good antimicrobial activity, it has lower
stability than other temporins, because it presents a trypto-
phan in its sequence.
Initially, TL was the only temporin with anti–gram-negative
activity, but today there are many other peptides with the same
antimicrobial activities and are more stable. These studies
demonstrate that, even with the advancement in scientific re-
search on the composition and antimicrobial activity of tem-
porins, further studies are necessary to wholly understand their
components and mechanisms of action.
The need for new and more effective antibiotic and anti-
fungal agents makes necessary the discovery and application
of new drugs based on natural peptides such as AMPs.
Future Prospectives
The AMPs are the future drugs and the promising alterna-
tive in the pharmacologic industry. Combination of AMPs
with nanotechnology could be the answer to all the resistant
pathogens that produce thousands of mortal diseases per year,
especially in poor and underdeveloped countries. New dis-
coveries in AMPs activities and efficiency are necessary to
incorporate more suitable alternatives in the field of medicines.
Temporins are a promising candidate for the improvement of
new drugs doe topical use and oral administration. This is the
next step in the investigation of these peptides that are not
deeply studied.
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Péptidos antimicrobianos de plantas. Rev Farm 2018;160:
28–46.
6. Conlon JM. Reflections on a systematic nomenclature for
antimicrobial peptides from the skins of frogs of the
family Ranidae. Peptides 2008;29:1815–1819.
7. Conlon JM, Kolodziejek J, Nowotny N. Antimicrobial
peptides from the skins of North American frogs. Biochim
Biophys Acta 2009;1788:1556–1563.
8. Conlon JM. Structural diversity and species distribution of
host-defense peptides in frog skin secretions. Cell Mol
Life Sci 2011;68:2303–2315.
9. Simmaco M, De Biase D, Severini C, et al. Purification
and characterization of bioactive peptides from skin ex-
tracts of Rana esculenta. Biochim Biophys Acta 1990;
1033:318–323.
10. Simmaco M, Mignogna G, Canofeni S, et al. Temporins,
antimicrobial peptides from the European red frog Rana
temporaria. Eur J Biochem 1996;242:788–792.
11. Krishnakumari V, Nagaraj R. Antimicrobial and hemo-
lytic activities of crabrolin, a 13-residue peptide from the
venom of the European hornet, Vespa crabro, and its
analogs. J Pept Res 1997;50:88–93.
12. Argiolas A, Pisano JJ. Isolation and characterization of
two new peptides, mastoparan C and crabrolin, from the
venom of the European hornet, Vespa crabro. J Biol Chem
1984;259:10106–10111.
13. das Neves RC, Mortari MR, Schwartz EF, et al. Anti-
microbial and antibiofilm effects of peptides from venom
of social wasp and scorpion on multidrug-resistant Aci-
netobacter baumannii. Toxins (Basel) 2019; www.mdpi
.com/2072-6651/11/4/216.
14. Konno K, Kazuma K, Rangel M, et al. New mastoparan
peptides in the venom of the solitary eumenine wasp
Eumenes micado. Toxins (Basel) 2019; www.mdpi.com/
2072-6651/11/3/155.
15. Konno K, Hisada M, Fontana R, et al. Anoplin, a novel
antimicrobial peptide from the venom of the solitary wasp
Anoplius samariensis. Biochim Biophys Acta 2001;1550:
70–80.
16. Xu X, Li J, Lu Q, et al. Two families of antimicrobial
peptides from wasp (Vespa magnifica) venom. Toxicon
2006;47:249–253.
17. Wade D, Silveira A, Silberring J, Kuusela P, et al. Tem-
porin antibiotics peptides: A review and derivation of a
consensus sequence. Protein Pept Lett 2000;7:349–357.
18. Rinaldi AC, Conlon JM. Temporins. In: Kastin AJ (ed):
Anphibian/Skin Peptides, 2nd ed. London: Elsevier.
Handbook of Biologically Active Peptides, 2013, pps
400–406.
19. Ali MF, Lips KR, Knoop FC, et al. Antimicrobial peptides
and protease inhibitors in the skin secretions of the
crawfish frog, Rana areolata. Biochim Biophys Acta
2002;1601:55–63.
20. Conlon JM, Sonnevend A, Davidson C, et al. Host-
defense peptides isolated from the skin secretions of the
Northern red-legged frog Rana aurora aurora. Dev Comp
Immunol 2005;29:83–90.
21. Lu Y, Li J, Yu H, et al. Two families of antimicrobial
peptides with multiple functions from skin of rufous-
spotted torrent frog, Amolops loloensis. Peptides 2006;27:
3085–3091.
22. Wang M, Wang Y, Wang A, et al. Five novel antimi-
crobial peptides from skin secretions of the frog, Amolops
loloensis. Comp Biochem Physiol B Biochem Mol Biol
2010;155:72–76.
23. Conlon JM, Sonnevend A, Patel M, et al. Isolation of
peptides of the brevinin-1 family with potent candidacidal
activity from the skin secretions of the frog Rana boylii.
J Pept Res 2003;62:207–213.
24. Halverson T, Basir YJ, Knoop FC, Conlon JM. Purifica-
tion and characterization of antimicrobial peptides from
the skin of the North American green frog Rana clami-
tans. Peptides 2000;21:469-4676.
25. Shang D, Yu F, Li J, et al. Molecular cloning of cDNAs
encoding antimicrobial peptide precursors from the skin
of the Chinese brown frog, Rana chensinensis. Zoolog Sci
2009;26:220-226.
26. Jin LL, Li Q, Song SS, et al. Characterization of antimi-
crobial peptides isolated from the skin of the Chinese frog,
Rana dybowskii. Comp Biochem Physiol B Biochem Mol
Biol 2009;154:174–178.
27. (a) CAMPD. Collection of Antimicrobial Peptides Data-
base (2019a). www.camp.bicnirrh.res.in/seqDisp.php?id=
CAMPSQ4462. (b) CAMPD. Collection of Antimicrobial
Peptides Database (2019b). www.camp.bicnirrh.res.in/
seqDisp.php?id=CAMPSQ4463.
28. Yang X, Xia J, Yu Z, et al. Characterization of diverse
antimicrobial peptides in skin secretions of Chungan tor-
rent frog Amolops chunganensis. Peptides 2012;38:41–53.
29. Conlon JM, Al-Dhaheri A, Al-Mutawa E, et al. Peptide
defenses of the Cascades frog Rana cascadae: Implica-
tions for the evolutionary history of frogs of the Amerana
species group. Peptides 2007;28:1268–1274.
30. Conlon JM, Meetani MA, Coquet L, et al. Antimicrobial
peptides from the skin secretions of the New World frogs
Lithobates capito and Lithobates warszewitschii (Rani-
dae). Peptides 2009;30:1775–1781.
31. Conlon JM, Al-Ghafari N, Coquet L, et al. Evidence from
peptidomic analysis of skin secretions that the red-legged
frogs, Rana aurora draytonii and Rana aurora aurora, are
distinct species. Peptides 2006;27:1305–1312.
32. Conlon JM, Kolodziejek J, Nowotny N, et al. Cytolytic
peptides belonging to the brevinin-1 and brevinin-2 fam-
ilies isolated from the skin of the Japanese brown frog,
Rana dybowskii. Toxicon 2007;50:746–756.
33. Ali MF, Knoop FC, Vaudry H, Conlon JM. Character-
ization of novel antimicrobial peptides from the skins of
frogs of the Rana esculenta complex. Peptides 2003;24:
955–961.
34. Chen X, Wang H, Yang M, et al. Identification and bio-
activity evaluation of two novel temporins from the skin
secretion of the European edible frog, Pelophylax kl es-
culentus. Biochem Biophys Res Commun 2016;476:566–
573.
35. Kim JB, Halverson T, Basir YJ, et al. Purification and
characterization of antimicrobial and vasorelaxant pep-
tides from skin extracts and skin secretions of the North
American pig frog Rana grylio. Regul Pept 2000;90:53–
60.
36. Zhou J, McClean S, Thompson A, et al. Purification and
characterization of novel antimicrobial peptides from the
skin secretion of Hylarana guentheri. Peptides 2006;27:
3077–3084.




















































37. Conlon JM, Power GJ, Abdel-Wahab YH, et al. A potent,
non-toxic insulin-releasing peptide isolated from an ex-
tract of the skin of the Asian frog, Hylarana guntheri
(Anura: Ranidae). Regul Pept 2008;151:153–159.
38. Conlon JM, Coquet L, Leprince J, et al. Peptidomic
analysis of skin secretions from Rana heckscheri and Rana
okaloosae provides insight into phylogenetic relationships
among frogs of the Aquarana species group. Regul Pept
2007;138:87–93.
39. Wang H, Yu Z, Hu Y, et al. Novel antimicrobial peptides
isolated from the skin secretions of Hainan odorous frog,
Odorrana hainanensis. Peptides 2012;35:285–290.
40. Isaacson T, Soto A, Iwamuro S, et al. Antimicrobial
peptides with atypical structural features from the skin of
the Japanese brown frog Rana japonica. Peptides 2002;
23:419–425.
41. Goraya J, Wang Y, Li Z, et al. Peptides with antimicrobial
activity from four different families isolated from the
skins of the North American frogs Rana luteiventris, Rana
berlandieri and Rana pipiens. Eur J Biochem 2000;267:
894–900.
42. Wang G, Wang Y, Ma D, et al. Five novel antimicrobial
peptides from the Kuhl’s wart frog skin secretions, Lim-
nonectes kuhlii. Mol Biol Rep 2013;40:1097–1102.
43. Wang H, Lu Y, Zhang X, et al. The novel antimicrobial
peptides from skin of Chinese broad-folded frog, Hylar-
ana latouchii (Anura: Ranidae). Peptides 2009;30:273–
282.
44. Wang H, Yu Z, Hu Y, et al. Molecular cloning and
characterization of antimicrobial peptides from skin of the
broad-folded frog, Hylarana latouchii. Biochimie 2012;
94:1317–1326.
45. Wang H, Yan X, Yu H, et al. Isolation, characterization
and molecular cloning of new antimicrobial peptides be-
longing to the brevinin-1 and temporin families from the
skin of Hylarana latouchii (Anura: Ranidae). Biochimie
2009;91:540–547.
46. Rollins-Smith LA, Woodhams DC, Reinert LK, et al.
Antimicrobial peptide defenses of the mountain yellow-
legged frog (Rana muscosa). Dev Comp Immunol 2006;
30:831–842.
47. Kim JB, Iwamuro S, Knoop FC, Conlon JM. Anti-
microbial peptides from the skin of the Japanese moun-
tain brown frog, Rana ornativentris. J Pept Res 2001;58:
349–356.
48. Ohnuma A, Conlon JM, Yamaguchi K, et al. Anti-
microbial peptides from the skin of the Japanese mountain
brown frog Rana ornativentris: Evidence for polymor-
phism among preprotemporin mRNAs. Peptides 2007;28:
524–532.
49. Conlon JM, Coquet L, Leprince J, et al. Peptidomic anal-
ysis of skin secretions from Rana heckscheri and Rana
okaloosae provides insight into phylogenetic relationships
among frogs of the Aquarana species group. Regul Pept
2007;138:87–93.
50. Zhou M, Wang L, Owens DE, et al. Rapid identification of
precursor cDNAs encoding five structural classes of an-
timicrobial peptides from pickerel frog (Rana palustris)
skin secretion by single step ‘‘shotgun’’ cloning. Peptides
2007;28:1605–1610.
51. Conlon JM, Sonnevend A, Patel M, et al. A family of
brevinin-2 peptides with potent activity against Pseudomonas
aeruginosa from the skin of the Hokkaido frog, Rana pirica.
Regul Pept 2004;118:135–141.
52. Conlon JM, Mechkarska M, Ahmed E, et al. Host defense
peptides in skin secretions of the Oregon spotted frog
Rana pretiosa: Implications for species resistance to
chytridiomycosis. Dev Comp Immunol 2011;35:644–649.
53. Conlon JM, Kolodziejek J, Nowotny N, et al. Character-
ization of antimicrobial peptides from the skin secretions
of the Malaysian frogs, Odorrana hosii and Hylarana
picturata (Anura: Ranidae). Toxicon 2008;52:465–473.
54. Asoodeh A, Zardini HZ, Chamani J. Identification and
characterization of two novel antimicrobial peptides,
temporin-Ra and temporin-Rb, from skin secretions of the
marsh frog (Rana ridibunda). J Pept Sci 2012;18:10–16.
55. Ma Y, Liu C, Liu X, et al. Peptidomics and genomics
analysis of novel antimicrobial peptides from the frog,
Rana nigrovittata. Genomics 2010;95:66–71.
56. Abbassi F, Oury B, Blasco T, et al. Isolation, character-
ization and molecular cloning of new temporins from the
skin of the North African ranid Pelophylax saharica.
Peptides 2008;29:1526–1533.
57. Suzuki H, Iwamuro S, Ohnuma A, et al. Expression of genes
encoding antimicrobial and bradykinin-related peptides in
skin of the stream brown frog Rana sakuraii. Peptides 2007;
28:505–514.
58. Bevier CR, Sonnevend A, Kolodziejek J, et al. Purification
and characterization of antimicrobial peptides from the
skin secretions of the mink frog (Rana septentrionalis).
Comp Biochem Physiol C Toxicol Pharmacol 2004;139:
31–38.
59. Abbassi F, Galanth C, Amiche M, , et al. Solution structure
and model membrane interactions of temporins-SH, antimi-
crobial peptides from amphibian skin. A NMR spectroscopy
and differential scanning calorimetry study. Biochemistry
2008;47:10513–10525.
60. Abbassi F, Raja Z, Oury B, et al. Antibacterial and
leishmanicidal activities of temporin-SHd, a 17-residue
long membrane-damaging peptide. Biochimie 2013;95:
388–399.
61. Yang X, Hu Y, Xu S, et al. Identification of multiple
antimicrobial peptides from the skin of fine-spined frog,
Hylarana spinulosa (Ranidae). Biochimie 2013;95:2429–
2436.
62. Conlon JM, Sonnevend A, Patel M, et al. A melittin-
related peptide from the skin of the Japanese frog, Rana
tagoi, with antimicrobial and cytolytic properties. Bio-
chem Biophys Res Commun 2003;306:496–500.
63. Iwamuro S, Nakamura M, Ohnuma A, Conlon JM. Mo-
lecular cloning and sequence analyses of preprotemporin
mRNAs containing premature stop codons from extra-
dermal tissues of Rana tagoi. Peptides 2006;27:2124–
2128.
64. Conlon JM, Al-Ghaferi N, Abraham B, et al. Anti-
microbial peptides from the skin of the Tsushima brown
frog Rana tsushimensis. Comp Biochem Physiol C Tox-
icol Pharmacol 2006;143:42–49.
65. Chen T, Zhou M, Rao P, et al. The Chinese bamboo leaf
odorous frog (Rana (Odorrana) versabilis) and North
American Rana frogs share the same families of skin
antimicrobial peptides. Peptides 2006;27:1738–1744.
66. Conlon JM, Abraham B, Sonnevend A, et al. Purification
and characterization of antimicrobial peptides from the
skin secretions of the carpenter frog Rana virgatipes
(Ranidae, Aquarana). Regul Pept 2005;131:38–45.
67. Mangoni ML, Rinaldi AC, Di Giulio A, et al. Structure-
function relationships of temporins, small antimicrobial




















































peptides from amphibian skin. Eur J Biochem 2000;267:
1447–1454.
68. Wade D, Silberring J, Soliymani R, et al. Antibacterial
activities of temporin A analogs. FEBS Lett 2000;479:
6–9.
69. D’Abramo M, Rinaldi AC, Bozzi A, et al. Conformational
behavior of temporin A and temporin L in aqueous solu-
tion: A computational/experimental study. Biopolymers
2006;81:215–224.
70. Manzo G, Ferguson PM, Gustilo BV, et al. Minor se-
quence modifications in temporin B cause drastic changes
in antibacterial potency and selectivity by fundamentally
altering membrane activity. Sci Rep 2019;9:1385.
71. Abbassi F, Lequin O, Piesse C, et al. Temporin-SHf, a
new type of phe-rich and hydrophobic ultrashort antimi-
crobial peptide. J Biol Chem 2010;285:16880–16892.
72. Giacometti A, Cirioni O, Ghiselli R, et al. Interaction of
antimicrobial peptide temporin L with lipopolysaccharide
in vitro and in experimental rat models of septic shock
caused by gram-negative bacteria. Antimicrob Agents
Chemother 2006;50:2478–2486.
73. Rollins-Smith LA, Carey C, Conlon JM, et al. Activities
of temporin family peptides against the chytrid fungus
(Batrachochytrium dendrobatidis) associated with global
amphibian declines. Antimicrob Agents Chemother 2003;
47:1157–1160.
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